**The protective effect of lidocaine on lipopolysaccharide-induced acute lung injury in rats through NF-κB and p38 MAPK signaling pathway and excessive inflammatory responses**

L.-J. CHEN¹, Y.-B. DING², P.-L. MA³, S.-H. JIANG⁴, K.-Z. LI², A.-Z. LI², M.-C. LI², C.-X. SHI², J. DU², H.-D. ZHOU⁵

¹Operating Room, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China
²Department of Anesthesiology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China
³Department of Anesthesiology, Qingdao Hiser Medical Center, Qingdao, China
⁴Muping District Center for Disease Control and Prevention, Yantai, China
⁵Department of Anesthesiology, Zhejiang Cancer Hospital, Hangzhou, China

**Abstract.** – OBJECTIVE: Acute lung injury is a severe disease with a high rate of mortality, leading to more important illness. We aimed at exploring the protective role and potential mechanisms of lidocaine on lipopolysaccharide (LPS)-induced acute lung injury (ALI).

MATERIALS AND METHODS: Sprague Dawley (SD) rats were randomly assigned to control group receiving 0.9% saline solution, LPS group treated with 4 mg/kg LPS i.p., LPS + lidocaine (treated with 4 mg/kg LPS i.p. followed by giving 1 mg/kg, 3 mg/kg, 5 mg/kg of lidocaine i.v.). Lung specimens and the bronchoalveolar lavage fluid (BALF) were collected for histopathological examination and biochemical analysis 12 h after LPS induction. The cytokines expression of TNF-α, IL-6 and MCP-1 was measured by ELISA. In addition, the malondialdehyde (MDA) content, the activities of total antioxidant capacity (T-AOC) and superoxide dismutase (SOD) in lung tissues were also detected using ELISA. The protein expressions of p38, p-p38, p65, p-p65 and IκB were analyzed by Western blot.

RESULTS: The results indicated that after lidocaine treatment was able to decrease significantly wet-to-dry (W/D) ratio and ameliorate the histopathologic damage. Additionally, total protein content and the number of leukocytes in BALF significantly decreased. ELISA result indicated that the levels of TNF-α, IL-6 and MCP-1 in BALF were markedly suppressed. Meanwhile, the activities of T-AOC and SOD in lung tissues significantly increased, while the content of MDA significantly decreased after treatment with lidocaine. Moreover, Western blot suggested that lidocaine inhibited phosphorylation of NF-κB p65 and p38 MAPK.

CONCLUSIONS: Therefore, lidocaine could ameliorate the LPS-induced lung injury via NF-κB/p38 MAPK signaling and excessive inflammatory responses, providing a potential for becoming the anti-inflammatory agent against lung injury.

**Key Words:** Acute lung injury, Lidocaine, Lipopolysaccharide, NF-κB, p38 MAPK.

**Introduction**

Acute lung injury (ALI) is the damage of structure and serious oxidation disorders caused by various pathogens, exhibited clinical syndrome, such as respiratory distress and dispersive lung infiltration. ALI and its more severe form, acute respiratory distress syndrome (ARDS), are characterized by severe hypoxemia, pulmonary edema and neutrophil accumulation in the lung, which are the prominent source of morbidity and mortality in critically ill patients. Sepsis is a major cause of ALI, and lipopolysaccharide (LPS), a primary component of outer membrane of gram-negative bacteria and predominant inducer of inflammatory responses to these bacteria, can reproduce the features of human ALI in mice. Therefore, intratracheal administration of...

LPS into lungs has been extensively accepted as an ideal pharmacological research model of ALI. Inflammation and oxidative stress are known to play a vital effect in the pathogenesis of ALI. Various inflammatory mediators, such as monocytic chemotactic protein 1 (MCP-1), tumor necrosis factor-α (TNF-α), and interleukin 16 (IL-16), have been implicated in LPS-induced ALI. The previous study showed that release of the mediators mentioned above was involved in the activation of NF-κB signaling pathway. In addition, inflammatory mediator production was also associated with activation of the p38 MAPK pathway. Since the expression of pro-inflammatory mediators is tightly regulated at a transcriptional level via the MAPK and NF-κB signaling pathways, the targeted inhibition of the activity of NF-κB and p38 MAPK has been identified as a new therapeutic method for inflammatory diseases. Many studies have exhibited the anti-inflammatory effect of lidocaine. Lahat et al. reported that they have proved that lidocaine could suppress the expression of the pro-inflammatory cytokines, such as tumor necrosis factor (TNF-α) and interleukin (IL-2) in T-cell. Previous researches have demonstrated that lidocaine, a common local anesthetic drug, has notable anti-inflammatory properties in addition to their direct anesthetic activity in vitro. In 2008, Gu et al. demonstrated that lidocaine could significantly decrease the phosphorylation of p38 MAPK in the activated microglia. Wang et al. reported that they have proved that lidocaine could suppress the expression of the pro-inflammatory cytokines, such as tumor necrosis factor (TNF-α) and interleukin (IL-2) in T-cell. Previous researches have demonstrated that lidocaine, a common local anesthetic drug, has notable anti-inflammatory properties in addition to their direct anesthetic activity in vitro. In 2008, Gu et al. demonstrated that lidocaine could significantly decrease the phosphorylation of p38 MAPK in the activated microglia.

Materials and Methods

Animal Group

Male Sprague Dawley (SD) rats weighting 250-280 g (aged 7-8 weeks) were purchased from Experimental Animal Center of Suzhou Aiermaite Technology Co. Ltd. (SPF grade, Certificate No. SCXK201500004). All animals were treated in accordance with the Care and Use of Laboratory Animals. Rats were randomly divided into the following five groups (n=10): control group, LPS group, LPS + lidocaine (1 mg/kg, 3 mg/kg, and 5 mg/kg) groups. According to guidelines and the terms of all relevant local legislation, the LPS-induced ALI model was prepared according to the method of Heidemann and Glibetic. In this study, the dose selected was based on the preliminary experiments. Firstly, rats were anesthetized with 10% chloral hydrate (350 mg/kg, i.p) followed by receiving i.p. 4 mg/kg of lipopolysaccharide (2 mg/ml, Sigma-Aldrich, St. Louis, MO, USA). The 10 rats in control group received the same volume of 0.9% saline solution. Then, the rats in the LPS + lidocaine group were injected lidocaine (Sigma-Aldrich, St. Louis, MO, USA) of 1 mg/kg, 3 mg/kg, and 5 mg/kg through the tail vein 30 min after LPS administration. Meanwhile, the rats in control and LPS groups were given an equal volume of 0.9% saline solution. After LPS administration for 12 h, the rats were anesthetized with 10% chloral hydrate and sacrificed. Then, the lungs of rats were harvested and stored in liquid nitrogen for later use.

Bronchoalveolar Lavage Fluid (BALF) Collection and Measurement of BALF Cytokines

12 h after LPS administration, rats were anesthetized and provided with a plastic cannula inserted to the trachea. BALF was obtained by washing the airway five times with 0.7 ml ice-cold phosphate-buffered saline (PBS). The total number of leukocyte in BALF was counted using a hemocytometer. Subsequently, BALF samples were centrifuged at 1500 rpm, 4°C for 10 min, and cytopsin samples were prepared from the cell pellet. The supernatant samples were used to quantify the cytokines levels of rats tumor necrosis factor-α (TNF-α), interleukin (IL-6) and monocytic chemotactic protein-1 (MCP-1) levels in BALF using ELISA according to the manufacturer’s instructions (Nanjing Jiancheng Bioengineering Co., Nanjing, China).

Lung Wet/Dry Ratio

Lungs were harvested 12 h after LPS challenge and weighed immediately to obtain the wet weight value. After that, lungs were dried in an incubator at 65°C for 72 h to obtain the dry weight. Finally,
The protective effect of lidocaine on rats lung injury

The ratio of lung-wet weight to dry weight was calculated and recorded.

**Histological Evaluation**

Lung tissues were inflated under a pressure of 23 cm H$_2$O with 4% (v/v) paraformaldehyde and then embedded in paraffin. 4-μm thick sections were prepared using a microtome, stained with hematoxylin and eosin (HE) solution, respectively, and observed under light microscopic. Lung injury was graded by ALI scoring system as described previously$^{4,18}$. Three categories including infiltration of inflammatory cells, thickness of the alveolar walls and hemorrhage were graded in a blinded manner according to a five-point scale: 0 = minimal damage; 1 = mild damage; 2 = moderate damage; 3 = severe damage; 4 = maximal damage. The total score was calculated by adding up the individual scores of each category.

**Quantification of T-AOC, SOD activity and MDA Content in Lung Tissue**

The malondialdehyde (MDA) content, the activities of total antioxidant capacity (T-AOC), and superoxide dismutase (SOD) in lung tissues were measured strictly using ELISA kits (Nanjing Jiancheng Co., Nanjing, China) according to the manufacturer’s instructions.

**Western Blotting Analysis**

Lung tissues were harvested at 12 h after LPS administration; then, non-pulmonary tissues were cleared and frozen at -80°C. Tissue samples were homogenized with RIPA lysis buffer (SolarBio, Beijing, China) and centrifuged at 800 g, 4°C for 10 min. The protein concentration was detected through bicinchoninic acid (BCA) protein assay kit (Chengdu Must Biotechnology Co., Ltd., Chengdu, China). The equivalent amounts of protein (80 μg) were subsequently separated by 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gels, and transferred onto a polyvinylidene difluoride (PVDF) membrane (Wuhan Boster Biological Technology, Ltd., Wuhan, China). The membranes were blocked by 5% non-fat dry milk at room temperature for 2 h and incubated overnight at 4°C with primary antibodies p38 and p-p38 (1:1000, Cell Signaling Technology, Danvers, MA, USA), p65 and p-p65 (1:500, Cell Signaling Technology Danvers, MA, USA) and β-actin (1:1000, Cell Signaling Technology, Danvers, MA, USA) antibody. Subsequently, the membranes were incubated with secondary antibody (1:1000, Cell Signaling Technology, Danvers, MA, USA), followed by detection with chemiluminescence and visualization by enhanced chemiluminescence (ECL) kit (Amersham, Little Chalfont, UK). The protein bands were analyzed by LabImage version 2.7.1 (Kapelan GmbH, Halle, Germany).

**Statistical Analysis**

Statistical analysis was implemented using SPSS18.0 software (SPSS Inc., Chicago, IL, USA). Data were expressed as the mean ± SD; differences between groups were evaluated by one-way analysis of variance (ANOVA) followed by Duncan’s new multiple range method or Newman-Keuls test. $p < 0.05$ was considered as statistically significant.

**Results**

**Effects of Lidocaine on Lung Histopathologic Changes**

To assess the effect of lidocaine on LPS-induced ALI rats, HE staining was applied to observe the lung histologic changes with or without lidocaine. Lung tissues in the LPS group were significantly damaged, mainly exhibited inflammatory infiltration, interstitial edema, thickening of the alveolar wall, and hemorrhage (Figure 1B). However, the treatment of lidocaine after LPS challenge ameliorated the pulmonary injury (Figure 1C-E). Additionally, the lung injury score was also evaluated. The lung injury score of 4.7 in LPS group was significantly higher than that of LPS+lidocaine group ($p < 0.01$), and the scores showed a markedly downward trend with the gradual increase of lidocaine concentration (Figure 1F).

**Lidocaine Ameliorated LPS-induced Acute Lung Injury**

As for the assessment of non-cardiogenic pulmonary edema, the lung W/D ratio is a critical feature of ALI. As shown in Figure 2A, W/D ratio in LPS group significantly increased compared with the control group (5.6 vs. 4.3, $p < 0.01$). However, lidocaine administration (1, 3 or 5 mg/kg) significantly reduced the W/D ratio compared with LPS group ($p < 0.01$ or $p < 0.05$). The W/D ratio was approximately 4.9, 4.7, and 4.5, corresponding to 1 mg/kg, 5 mg/kg and 5 mg/kg of lidocaine, respectively. Meanwhile, the ameliorations in pulmonary were revealed in a dose-dependent manner. In addition, cellular counts and proteins are also important feature to assess the inflammatory response. The number of leukocyte and the total protein were about 6.5×10$^7$/l
and 133 μg/ml in LPS group, respectively, exhibiting remarkable increase in comparison with control group ($p < 0.05$) (Figure 2B-C). However, lidocaine treatment decreased both number of leukocyte and total protein than those in LPS group ($p < 0.05$), especially in 5 mg/kg of LSP. The number of leukocyte and total protein was about 4.9×10⁷/l and 75 μg/ml, respectively, which were lower than other LSP + lidocaine groups.

**Lidocaine Down-Regulates TNF-α, IL-6 and MCP-1 in BALF**

To identify the anti-inflammatory property of lidocaine, the level of inflammatory mediators including TNF-α, IL-6 and MCP-1 in BALF was measured by ELISA method. The concentration of TNF-α, IL-6, and MCP-1 of LSP groups in BALF were markedly higher than control group (155 pg/ml vs. 50 pg/ml, 425 pg/ml vs. 65 pg/ml, 410 pg/ml vs. 75 pg/ml, respectively, $p < 0.05$ or $p < 0.01$) (Figure 3). The expression of these mediators after lidocaine injection was decreased than those in LPS group ($p < 0.05$ or $p < 0.01$). Additionally, the effect of lidocaine on pulmonary inflammatory showed a dose-dependent manner. At dose of 5 mg/kg lidocaine, the expression levels of TNF-α, IL-6, and MCP-1, were approximately 85 pg/ml, 225 pg/ml, and 260 pg/ml.

---

**Figure 1.** Lidocaine improved LPS-caused ALI 12 h after treatment of LPS ($\times$200). 4-μm thick sections of lung tissue were analyzed by HE staining. (A) Control group; (B) LPS group; (C) LPS+1 mg/ml lidocaine group; (D) LPS+3 mg lidocaine group; (E) LPS+5 mg lidocaine group; (F) Lung injury scores. Data were expressed as mean ± SD. **$p < 0.01$ vs. control group; ##$p < 0.05$ vs. LPS group.
The protective effect of lidocaine on rats lung injury

Effect of Lidocaine on NF-κB Expression in Lung Tissue

Phosphorylation of NF-κB prompts the transcription of most pro-inflammatory cytokines, playing a pivotal role in the pathogenesis of ALI\(^9\). As shown in Figure 5A and C, LPS stimulation significantly increased p65 phosphorylation up to around 4.5 (\(p < 0.01\)), while lidocaine significantly reduced the p-p65 induction by LPS, especially in 5 mg/kg lidocaine. In parallel with serine phosphorylation of NF-κB and p65, the effect of lidocaine on Iκ-B degradation (Figure 5B) was also examined. The result showed that lidocaine significantly inhibited Iκ-B degradation in a dose-dependent manner.

Effect of Lidocaine on T-AOC, SOD Activity and MDA Content in Lung Tissue

Oxidative stress has been recognized as a critical factor of pathophysiology in LPS-induced ALI. In this study, the activities of SOD and MDA were examined. As shown in Figure 4, the activity of T-AOC and SOD in LPS group (0.4 U/g and 63 U/g) were significantly declined compared with the control group (\(p < 0.01\)), along with the noticeable rise of MDA content (2.6 U/g, \(p < 0.01\)). Administration of lidocaine markedly increased the activity of T-AOC and SOD (\(p < 0.05\) or \(p < 0.01\)), and decreased the content of MDA (\(p < 0.05\) or \(p < 0.01\)) with a dose-dependent manner.

Figure 2. The inhibitory effects of lidocaine on LPS-induced acute lung injury. Male Sprague Dawley rats received lidocaine with a dose of 1 mg/kg, 3 mg/kg, and 5 mg/kg 30 min after LPS administration. (A) Levels of lung W/D ratio after lidocaine injection via tail vein. (B) Number of leukocyte in BALF after treatment of LPS for 12 h. (C) The expression of total protein in lung tissues. After treatment of LPS for 12 h, the lung tissues were collected and analyzed by Western blot. Data are presented as mean ± SD (\(n=10\)). \(* p < 0.05\), \(" p < 0.01\) vs. control group; \(# p < 0.05\), \("# p < 0.01\) vs. LPS group.
**Effect of Lidocaine on p38 MAPK Expression in Lung Tissue**

p38 MAPK is independent of its phosphorylation state, and has been reported to participate in inflammation and the activation of NF-κB. As illustrated in Figure 5D, compared with control group, p38 phosphorylation evidently increased after LPS challenge \((p < 0.01)\). The ratio of p-p38/p38 was about 4.6. Giving a different dose of lidocaine, we found that lidocaine significantly reduced p38 phosphorylation compared with the LPS group \((p < 0.05\) or \(p < 0.01)\).

**Discussion**

ALI, a devastating disease, is responsible for significant morbidity and mortality; nevertheless, there are still few effective drugs in the clinic. LPS was recognized as one of the mainly pro-inflammatory reaction factors in infection diseases. Previous studies demonstrated that LPS possesses strong biological activities that could induce the inflammatory response and even result in ALI. We uncovered that administration of lidocaine attenuated LPS-induced ALI in mice. Lidocaine inhibited the deterioration of pulmonary edema, oxidative stress damage and suppressed the expression of pro-inflammatory mediators such as TNF-α, IL-6, and MCP-1 via two different pathways of NF-κB and p38 MAPK.

Pulmonary edema, the permeability change, and neutrophils infiltration, are the most important pathological findings in ALI. For quantifying the magnitude of pulmonary edema, the lung W/D ratio was evaluated. We found that the lung W/D ratio in LSP + lidocaine group was notably lower than the LPS group, which indicated that lidocaine attenuated the development of pulmonary edema. In addition, we observed a signi-

![Figure 3](image-url)
The protective effect of lidocaine on rats lung injury

A significant decrease in the number of leukocyte and the total protein after lidocaine administration. The result showed that lidocaine decreased the lung vascular permeability and neutrophils infiltration. Furthermore, these results were supported by lung histological evaluation, which showed that lidocaine markedly attenuated the histological changes including inflammatory infiltration, interstitial edema, thickening of the alveolar wall and hemorrhage. These results demonstrated the protective effects of lidocaine against LPS-induced ALI.

Evidence indicated pro-inflammatory mediators, including TNF-α, IL-6, and MCP-1 participate in the early development of inflammation and play a crucial role in ALI. Both TNF-α and IL-6 are the main markers of acute inflammatory response. MCP-1, a chemokine mainly expressed by alveolar macrophages and pulmonary vascular endothelial cells in the lung, was quickly up-regulated by inflammation stimuli, leading to the recruitment of more inflammatory cells, particularly neutrophils and macrophages, infiltrating into the damaged tissues. Our study showed that the TNF-α, IL-6, and MCP-1 level increased in BALF after LPS challenge. However, the releases of these pro-inflammatory mediators were inhibited by lidocaine administration and its effect was in a dose-dependent manner. These results suggested that the amelioration of LPS-induced ALI by lidocaine might be, at least in part, associated with the reduction of TNF-α, IL-6, and MCP-1 production.

Additionally, NF-κB activation plays a key role in the production of inflammatory cytokines. Wright and Christman reported that the inhibition of NF-κB activation can reduce its downstream inflammatory cytokine levels and contributes to ameliorate ALI. Under normal physiological conditions, NF-κB is sequestered in the cytoplasm by its inhibitor IκB. Stimulated by LPS induces the phosphorylation of p65, ente-
ring the nucleus and regulating the expression of inflammatory mediators. We demonstrated that LPS stimulation significantly increased the phosphorylation of p65 and IκBα degradation. However, lidocaine treatment inhibited IκBα degradation and p65 phosphorylation. Moreover, MAPK, including ERK, JNK and p38 MAPK, have been demonstrated to play a crucial role in signal transduction pathways, regulation of cytokine release, and participation in the activation of NF-κB in LPS-induced ALI. Among all of those, p38 MAPK pathway is reported to be activated by pro-inflammatory cytokines, such as TNF-α and IL-6. In this study, the result showed p38 MAPK was activated in LPS-induced lung injury. However, lidocaine treatment markedly suppressed LPS-induced p38 phosphorylation. These results indicated that blocking p38 MAPK and NF-κB signaling pathways might be the main reasons of lidocaine abatement of pulmonary inflammation.
Furthermore, excessive oxidative damage also plays a proven role in the pathogenesis of ALI. T-AOC is an anti-oxidative biomarker representing the level of enzyme and non-enzyme original antioxidant in the body. SOD is also extensively used as a biochemical indicator of pathological states associated with oxidative stress. In addition, MDA is a degradation product of the oxygen-derived free radicals and lipid oxidation, which reflects the damage caused by reactive oxygen species. We demonstrated that treatment with lidocaine raised the activation levels of T-AOC and SOD, while reduced the content of MDA. These observations suggested that lidocaine is capable of reducing serious lung damage through inhibition oxidative stress.

Conclusions

The protective mechanism of lidocaine may be attributed partly to suppress the p38 AMPK/NF-κB signaling pathway. Lidocaine attenuated LPS-induced ALI in mice by the inhibition of inflammation and oxidative stress, which could be a new therapeutic agent for the prevention of acute lung injury.

Ethical Committee Approval

The research was conducted in accordance with the Declaration of Helsinki and Ethics Committee of The Affiliated Yantai Yuhuangding Hospital of Qingdao University.

Conflict of Interest

The Authors declare that they have no conflict of interest.

References


